Current Oncology (Jun 2024)

A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma

  • Agnes Stephanie Harahap,
  • Regina Stefani Roren,
  • Shofiyya Imtiyaz

DOI
https://doi.org/10.3390/curroncol31060252
Journal volume & issue
Vol. 31, no. 6
pp. 3311 – 3328

Abstract

Read online

Differentiated high-grade thyroid carcinoma (DHGTC) is a new subset within the spectrum of thyroid malignancies. This review aims to provide a comprehensive overview of DHGTC, focusing on its historical perspective, diagnosis, clinical characteristics, molecular profiles, management, and prognosis. DHGTC demonstrates an intermediate prognosis that falls between well-differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Previously unenumerated, this entity is now recognized for its significant impact. Patients with DHGTC often present at an older age with advanced disease and exhibit aggressive clinical behavior. Molecularly, DHGTC shares similarities with other thyroid malignancies, harboring driver mutations such as BRAFV600E and RAS, along with additional late mutations. The unique behavior and histologic features of DHGTC underscore the necessity of precise classification for prognostication and treatment selection. This highlights the critical importance of accurate diagnosis and recognition by pathologists to enrich future research on this entity further.

Keywords